Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Translating The Foreign Corrupt Practices Act Into Practice: U.S. DoJ/SEC Offer Pragmatic Enforcement Guide

This article was originally published in PharmAsia News

Executive Summary

The FCPA resource guide gives examples of cases the DoJ and SEC have decided not to prosecute and describes the hallmarks of an effective compliance program; PhRMA, GPhA among groups that were asking for more clarity.

You may also be interested in...

Case Studies: Several Patent And Registration Litigations Highlight What Not To Do In China

BEIJING - It is a common refrain now for companies that do business in China that the country's intellectual property protection regime, while not perfect, is improving. But a recent conference on regulatory and legal issues in Beijing provided some discouraging examples about the challenges companies face in dealing with patent litigation and import certification in China

J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe

Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act

Rx Drug Promotion: Potential Enforcement Worries

Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts